Innovations for microbiome targeting interventions â a patent landscape analysis indicating overall patenting activity decline and promising target disease areas
In: Beneficial MicrobesSearch for other papers by J.K. Timmis in
Current site
Google Scholar
Search for other papers by D. Flaherty Roussilhon in
Current site
Google Scholar
Search for other papers by L.H.M. van de Burgwal in
Current site
Google Scholar
The human microbiota have been implicated in the aetiology and remedy of a host of disorders. However, due to the pervasive uncertainty inherent in the field of microbiota-targeting interventions and associated issues with establishing rigorous safety and efficacy profiles, regulatory oversight is suboptimal. This can dissuade innovators from further exploring novel and much needed health interventions. Modification of regulatory protocols and practices requires focussed efforts and funding to build the evidence base around future regulatory needs. Such modification can be critically informed by identification of changes and trends in technology fields to facilitate identification of regulatory gaps. To this purpose, this study rigorously collected and analysed patent data from Espacenet â covering the years 2013-2018 â and created a patent landscape analysis of microbiome targeting interventions with a focus on medicinal products. Pertinent patenting activity has declined overall. While, in absolute terms, patents most frequently claimed inventions targeting disorders of the gut and alimentary tract, relative year-on-year interest increases have been substantial for cancer, and disorders of the (neuro-)muscular and respiratory systems â driven by the private sector. Academic stakeholders showed top interest in disorders of the metabolism, anti-infectives, and skeletal and dermatological diseases. Although medicinal preparation claims dominated our dataset, a third of patents claimed food preparations, while only 1% claimed application as a diagnostic. Finally, China is, by an inordinate margin, a market of particular interest for both domestic and foreign innovators, indicating that microbiome targeting intervention innovation for EU and US markets might be frustrated. This study is the first to empirically demonstrate that live biotherapeutic product innovation is decelerating and potentially frustrated, supporting the urgent need for improved regulatory standards. Our results indicate which disease areas deserve particular attention for research funding to facilitate proper regulatory appraisal in the near- to mid-term future.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
American Psychiatric Association (APA), 2013. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Association Publishing, Washington, DC, USA. American Society for Microbiology (ASM), 2021. ASM urges support for microbiome research in FY 2022 budget. 19 May 2021. Available at: https://tinyurl.com/2ajv3k87
-
Beconcini, P., 2021. New procedures indicate Chinaâs patent system is now focused on quality, not quantity, of patents. Squire Patton Boggs (US) LLP, Global IP and Technology Law Blog, 15 February 2021. Available at: https://tinyurl.com/yptmcvch
-
Berg, G., Rybakova, D., Fischer, D., Cernava, T., Vergès, M.-C.C., Charles, T., Chen, X., Cocolin, L., Eversole, K., Corral, G.H., Kazou, M., Kinkel, L., Lange, L., Lima, N., Loy, A., Macklin, J.A., Maguin, E., Mauchline, T., McClure, R., Mitter, B., Ryan, M., Sarand, I., Smidt, H., Schelkle, B., Roume, H., Kiran, G.S., Selvin, J., Souza, R.S.C.d., van Overbeek, L., Singh, B.K., Wagner, M., Walsh, A., Sessitsch, A. and Schloter, M., 2020. Microbiome definition re-visited: old concepts and new challenges. Microbiome 8: 103. https://doi.org/10.1186/s40168-020-00875-0
-
Bonino, D., Ciaramella, A. and Corno, F., 2010. Review of the state-of-the-art in patent information and forthcoming evolutions in intelligent patent informatics. World Patent Information 32: 30-38. https://doi.org/10.1016/j.wpi.2009.05.008
-
Brüssow, H., 2020. The relationship between the host genome, microbiome, and host phenotype. Environmental Microbiology 22: 1170-1173. https://doi.org/10.1111/1462-2920.14938
-
Bubela, T., Gold, E.R., Graff, G.D., Cahoy, D.R., Nicol, D. and Castle, D., 2013. Patent landscaping for life sciences innovation: toward consistent and transparent practices. Nature Biotechnology 31: 202-206. https://doi.org/10.1038/nbt.2521
-
Butler, M.I., Cryan, J.F. and Dinan, T.G., 2019. Man and the microbiome: a new theory of everything? Annual Review of Clinical Psychology 15: 371-398. https://doi.org/10.1146/annurev-clinpsy-050718-095432
-
Carlson, P.E., Jr., 2020. Regulatory considerations for fecal microbiota transplantation products. Cell Host and Microbe 27: 173-175. https://doi.org/10.1016/j.chom.2020.01.018
-
Carney, S.M., Clemente, J.C., Cox, M.J., Dickson, R.P., Huang, Y.J., Kitsios, G.D., Kloepfer, K.M., Leung, J.M., LeVan, T.D., Molyneaux, P.L., Moore, B.B., OâDwyer, D.N., Segal, L.N. and Garantziotis, S., 2019. Methods in lung microbiome research. American Journal of Respiratory Cell and Molecular Biology 62: 283-299. https://doi.org/10.1165/rcmb.2019-0273TR
-
Cavalheiro, G.M.d.C., Joia, L.A. and Van Veenstra, A.F., 2016. Examining the trajectory of a standard for patent classification: an institutional account of a technical cooperation between EPO and USPTO. Technology in Society 46: 10-17. https://doi.org/10.1016/j.techsoc.2016.04.004
-
Center for Biologics Evaluation and Research, 2016. Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information â guidance for industry. U.S. Department of Health and Human Services â Food and Drug Administration, Silver Spring, MD, USA.
-
CipherBio Data Team, 2021. 64 Microbiome biotechs raise $1.6 billion in investments. Available at: https://blog.cipherbio.com/microbiome/.
-
Clarke, N. and Jürgens, B., 2019. Landscape study on patent filing â chimeric antigen receptor T-cell immunotherapy. European Patent Office, Munich, Germany. Available at: https://tinyurl.com/3kaxj923.
-
Community Research and Development Information Service (CRDIS), 2022. Metagenomics of the human intestinal tract. Available at: https://cordis.europa.eu/project/id/201052.
-
Cordaillat-Simmons, M., Rouanet, A. and Pot, B., 2020. Live biotherapeutic products: the importance of a defined regulatory framework. Experimental and Molecular Medicine 52: 1397-1406. https://doi.org/10.1038/s12276-020-0437-6
-
Cryan, J.F., OâRiordan, K.J., Cowan, C.S.M., Sandhu, K.V., Bastiaanssen, T.F.S., Boehme, M., Codagnone, M.G., Cussotto, S., Fulling, C., Golubeva, A.V., Guzzetta, K.E., Jaggar, M., Long-Smith, C.M., Lyte, J. M., Martin, J.A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., OâConnor, R., Cruz-Pereira, J.S., Peterson, V.L., Rea, K., Ritz, N.L., Sherwin, E., Spichak, S., Teichman, E.M., van de Wouw, M., Ventura-Silva, A.P., Wallace-Fitzsimons, S.E., Hyland, N., Clarke, G. and Dinan, T.G., 2019. The microbiota-gut-brain axis. Physiological Reviews 99: 1877-2013. https://doi.org/10.1152/physrev.00018.2018
-
Davani-Davari, D., Negahdaripour, M., Karimzadeh, I., Seifan, M., Mohkam, M., Masoumi, S.J., Berenjian, A. and Ghasemi, Y., 2019. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods 8: 92. https://doi.org/10.3390/foods8030092
-
De Simone, C., 2019. The unregulated probiotic market. Clinical Gastroenterology and Hepatology 17: 809-817. https://doi.org/10.1016/j.cgh.2018.01.018
-
Dechezleprêtre, A., Ménière, Y. and Mohnen, M., 2017. International patent families: from application strategies to statistical indicators. Scientometrics 111: 793-828. https://doi.org/10.1007/s11192-017-2311-4
-
Dronkers, T.M.G., Ouwehand, A.C. and Rijkers, G.T., 2020. Global analysis of clinical trials with probiotics. Heliyon 6: e04467-e04467. https://doi.org/10.1016/j.heliyon.2020.e04467
-
Ehlers, L., Bannert, K., Rohde, S., Berlin, P., Reiner, J., Wiese, M., Doller, J., Lerch, M.M., Aghdassi, A.A., Meyer, F., Valentini, L., Agrifoglio, O., Metges, C.C., Lamprecht, G. and Jaster, R., 2020. Preclinical insights into the gut-skeletal muscle axis in chronic gastrointestinal diseases. Journal of Cellular and Molecular Medicine 24: 8304-8314. https://doi.org/10.1111/jcmm.15554
-
Faner, R., Sibila, O., AgustÃ, A., Bernasconi, E., Chalmers, J.D., Huffnagle, G.B., Manichanh, C., Molyneaux, P.L., Paredes, R., Pérez Brocal, V., Ponomarenko, J., Sethi, S., Dorca, J. and Monsó, E., 2017. The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal 49: 1602086. https://doi.org/10.1183/13993003.02086-2016
-
Feddema, J.J., van der Waal, M.B., Renes, M.J., Claassen, E. and van de Burgwal, L.H., 2021. To patent or not to patent? Consideration of the societal aspects of patenting across pharma-nutrition industries. PharmaNutrition 16: 1-3.
'To patent or not to patent? Consideration of the societal aspects of patenting across pharma-nutrition industries ' () 16 PharmaNutrition : 1 -3.
-
Foligné, B., Daniel, C. and Pot, B., 2013. Probiotics from research to market: the possibilities, risks and challenges. Current Opinion in Microbiology 16: 284-292. https://doi.org/10.1016/j.mib.2013.06.008
-
Food and Drug Administration (FDA), 2020. Safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse events likely due to transmission of pathogenic organisms. Available at: https://tinyurl.com/mtjm6jdb
-
Gilbert, J.A., Blaser, M.J., Caporaso, J.G., Jansson, J.K., Lynch, S.V. and Knight, R., 2018. Current understanding of the human microbiome. Nature Medicine 24: 392-400. https://doi.org/10.1038/nm.4517
-
Goldenberg, S.D. and Merrick, B., 2021. The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection. Therapeutic Advances in Infectious Disease 8: 2049936120981526. https://doi.org/10.1177/2049936120981526
-
Gunjur, A., 2020. Cancer and the microbiome. The Lancet Oncology 21: 888. https://doi.org/10.1016/S1470-2045(20)30351-X
-
Hanssen, N.M.J., De Vos, W.M. and Nieuwdorp, M., 2021. Fecal microbiota transplantation in human metabolic diseases: from a murky past to a bright future? Cell Metabolism 33: 1098-1110. https://doi.org/10.1016/j.cmet.2021.05.005
-
Huybrechts, I., Zouiouich, S., Loobuyck, A., Vandenbulcke, Z., Vogtmann, E., Pisanu, S., Iguacel, I., Scalbert, A., Indave, I., Smelov, V., Gunter, M.J. and Michels, N., 2020. The human microbiome in relation to cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiology Biomarkers and Prevention 29: 1856. https://doi.org/10.1158/1055-9965.EPI-20-0288
-
Javorsek, M., 2015. Average growth rate: Computation methods. UN ESCAP Stats Brief, April 2015 (7). Available at: https://tinyurl.com/3addhrs5
-
Jürgens, B. and Herrero-Solana, V., 2015. Espacenet, Patentscope and Depatisnet: a comparison approach. World Patent Information 42: 4-12. https://doi.org/10.1016/j.wpi.2015.05.004
-
Kohut, M., Leker, J., Bröring, S. and Sick, N., 2020. Start-ups as an indicator of early market convergence. Journal of Business Chemistry 17: 110-123. https://doi.org/10.17879/60119498365
-
Larsen, O.F.A. and Van de Burgwal, L.H.M., 2021. On the verge of a catastrophic collapse? the need for a multi-ecosystem approach to microbiome studies. Frontiers in Microbiology 12: 784797. https://doi.org/10.3389/fmicb.2021.784797
-
Larsen, O.F.A., Claassen, E. and Brummer, R.J., 2020. On the importance of intraindividual variation in nutritional research. Beneficial Microbes 11: 511-517. 10.3920/BM2020.0044 Latimer, M.T., 2004. Patenting inventions arising from biological research. Genome Biology 6: 203. https://doi.org/10.1186/gb-2004-6-1-203
-
Li, D., Gao, C., Zhang, F., Yang, R., Lan, C., Ma, Y. and Wang, J., 2020. Seven facts and five initiatives for gut microbiome research. Protein and Cell 11: 391-400. https://doi.org/10.1007/s13238-020-00697-8
-
Long, C.X. and Wang, J., 2019. Chinaâs patent promotion policies and its quality implications. Science and Public Policy46: 91-104. https://doi.org/10.1093/scipol/scy040
-
Manzoor, S.S., Doedens, A. and Burns, M.B., 2020. The promise and challenge of cancer microbiome research. Genome Biology 21: 131. https://doi.org/10.1186/s13059-020-02037-9
-
Merrick, B., Allen, L., Masirah M Zain, N., Forbes, B., Shawcross, D.L. and Goldenberg, S.D., 2020. Regulation, risk and safety of faecal microbiota transplant. Infection Prevention in Practice 2: 100069. https://doi.org/10.1016/j.infpip.2020.100069
-
Microbiome Interagency Working Group (MIWG), 2018. Interagency strategic plan for microbiome research FY 2018-2022. Available at: https://tinyurl.com/mr26xcvf
-
Moos, W.H., Faller, D.V., Harpp, D.N., Kanara, I., Pernokas, J., Powers, W.R. and Steliou, K., 2016. Microbiota and neurological disorders: a gut feeling. BioResearch Open Access 5: 137-145. https://doi.org/10.1089/biores.2016.0010
-
Mossialos, E., Ge, Y., Hu, J. and Wang, L., 2016. Pharmaceutical policy in China: challenges and opportunities for reform. WHO, Geneva, Switzerland.
'Pharmaceutical policy in China: challenges and opportunities for reform', ().
-
National Center for Biotechnology Information (NCBI), 2021. MESH â Diseases Category. Available at: https://www.ncbi.nlm.nih.gov/mesh/1000067.
-
National Science Foundation (NSF), 2021. Understanding the rules of life: microbiome interactions and mechanisms (URoL:MIM). Available at: https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505694.
-
NCCR Microbiomes, 2020. Harnessing microbial communities for health and the environment. Available at: https://tinyurl.com/yc823ph5.
-
Neevel, A.M.G., Urias, E., Claassen, E. and van de Burgwal, L.H.M., 2020. Quantity vs. quality: an assessment of the current pipeline for rabies. Tropical Medicine & International Health 25: 397-407. https://doi.org/10.1111/tmi.13367
-
National Library of Medicine (NLM), 2022. PubMed MeSH search: (âMicrobiotaâ[Mesh]) AND âTherapeuticsâ[Mesh]. Available at: https://tinyurl.com/2k5vwan3.
-
Proctor, L.M., Creasy, H.H., Fettweis, J.M., Lloyd-Price, J., Mahurkar, A., Zhou, W., Buck, G.A., Snyder, M.P., Strauss, J.F., Weinstock, G.M., White, O., Huttenhower, C. and The Integrative HMP (iHMP) Research Network Consortium, 2019. The integrative human microbiome project. Nature 569: 641-648. https://doi.org/10.1038/s41586-019-1238-8
-
Puebla-Barragan, S. and Reid, G., 2019. Forty-five-year evolution of probiotic therapy. Microbial Cell 6: 184-196. https://doi.org/10.15698/mic2019.04.673
-
Qualtrics, 2020. Sample size calculator. Available at: https://www.qualtrics.com/blog/calculating-sample-size/.
-
Quigley, E.M.M. and Gajula, P., 2020. Recent advances in modulating the microbiome. F1000 Research 9: 46. https://doi.org/10.12688/f1000research.20204.1
-
Rajan, A., 2021. Powered by venture funding, the microbiome market is ready for mainstream. BiopharmaTrend.com 15 April 2021. Available at: https://tinyurl.com/5efzknrz.
-
Ramezanpour, B., Riemens, T., van de Burgwal, L. and Claassen, E., 2015. An interdisciplinary analysis of genetically modified vaccines: from clinical trials to market. International Journal of Clinical Trials 2(4): 64-74. https://doi.org/10.18203/2349-3259.ijct20151235
-
Reijnders, D., Goossens, G.H., Hermes, G.D.A., Smidt, H., Zoetendal, E.G. and Blaak, E.E., 2018. Short-term microbiota manipulation and forearm substrate metabolism in obese men: a randomized, double-blind, placebo-controlled trial. Obesity Facts 11: 318-326. https://doi.org/10.1159/000492114
-
Rouanet, A., Bolca, S., Bru, A., Claes, I., Cvejic, H., Girgis, H., Harper, A., Lavergne, S.N., Mathys, S., Pane, M., Pot, B., Shortt, C., Alkema, W., Bezulowsky, C., Blanquet-Diot, S., Chassard, C., Claus, S.P., Hadida, B., Hemmingsen, C., Jeune, C., Lindman, B., Midzi, G., Mogna, L., Movitz, C., Nasir, N., Oberreither, M., Seegers, J.F.M.L., Sterkman, L., Valo, A., Vieville, F. and Cordaillat-Simmons, M., 2020. Live biotherapeutic products, a road map for safety assessment. Frontiers in Medicine 7: 237.
'Live biotherapeutic products, a road map for safety assessment ' () 7 Frontiers in Medicine : 237.
-
Sharma, A., Das, P., Buschmann, M. and Gilbert, J.A., 2020. The future of microbiome-based therapeutics in clinical applications. Clinical Pharmacology and Therapeutics 107: 123-128. https://doi.org/10.1002/cpt.1677
-
Smith, J.A., Arshad, Z., Trippe, A., Collins, G.S., Brindley, D.A. and Carr, A.J., 2018. The reporting items for patent landscapes statement. Nature Biotechnology 36: 1043-1047. https://doi.org/10.1038/nbt.4291
-
Sulaiman, I., Schuster, S. and Segal, L.N., 2020. Perspectives in lung microbiome research. Current Opinion in Microbiology 56: 24-29. https://doi.org/10.1016/j.mib.2020.06.001
-
Tan, X. and Johnson, S., 2019. Fecal microbiota transplantation (FMT) for C. difficile infection, just say ânoâ. Anaerobe 60: 102092. https://doi.org/10.1016/j.anaerobe.2019.102092
-
Ticinesi, A., Nouvenne, A., Cerundolo, N., Catania, P., Prati, B., Tana, C. and Meschi, T., 2019. Gut microbiota, muscle mass and function in aging: a focus on physical frailty and sarcopenia. Nutrients 11: 1633. https://doi.org/10.3390/nu11071633
-
Timmis, J.K., Van Der Waal, R.X., Herz, J., Van Der Waal, M.B., Claassen, E. and Van De Burgwal, L.H., 2021. Market knowledge and stakeholder considerations for the biopharmaceutics sector â incorporating user value and societal needs in therapeutic interventions. Health 13: 1365-1395. https://doi.org/10.4236/health.2021.1311099
-
Trajtenberg, M. and Jaffe, A.B., 2002. Patents, citations, and innovations: a window on the knowledge economy. The MIT Press, Cambridge, MA, USA. https://doi.org/10.7551/mitpress/5263.001.0001
-
Trippe, A., 2015. Guidelines for preparing patent landscape reports. Report 945. WIPO, Geneva, Switzerland. Available at: https://tinyurl.com/43xwhna9.
-
U.S. Census Bureau, 2021. China. Available at: https://www.census.gov/popclock/world/ch.
-
University of California Davis, 2021. Microbiome special research program. Available at: https://microbiome.ucdavis.edu/funding/seed-grant.
-
Van de Burgwal, L.H.M., Reperant, L.A., Osterhaus, A.D.M.E., Iancu, S.C., Pronker, E.S. and Claassen, E., 2016. Self-centric and altruistic unmet needs for ebola: barriers to international preparedness. Disaster Medicine and Public Health Preparedness 10: 644-648. https://doi.org/10.1017/dmp.2016.64
-
Van de Burgwal, L.H.M., Van der Waal, M.B. and Claassen, E., 2018. Accelerating microbiota product development: the societal impact value cycle as a conceptual model to shape and improve public-private valorization processes. PharmaNutrition 6: 157-168. https://doi.org/10.1016/j.phanu.2018.07.002
-
Van den Nieuwboer, M., van de Burgwal, L.H.M. and Claassen, E., 2016. A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: valorisation and improving the tech transfer cycle. PharmaNutrition 4: 9-18. https://doi.org/10.1016/j.phanu.2015.09.003
-
Van der Geest, A.M., Besseling-Van der Vaart, I., Schellinger-de Goede, E.M., Van der Waal, M.B., Claassen, E., Flach, J. and Van de Burgwal, L.H.M., 2021. Multispecies probiotics promote perceived human health and wellbeing: insights into the value of retrospective studies on user experiences. Beneficial Microbes 12: 413-430. https://doi.org/10.3920/bm2020.0162
-
Van der Waal, M.B., Veldhuizen, C.K., van der Waal, R.X., Claassen, E. and van de Burgwal, L.H.M., 2020. A critical appreciation of intangible resources in PharmaNutrition. PharmaNutrition 13: 100208. https://doi.org/10.1016/j.phanu.2020.100208
-
Van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G. de Vos, W.M., Visser, C.E., Kuijper, E.J., Bartelsman, J.F., Tijssen, J.G., Speelman, P., Dijkgraaf, M.G. and Keller, J.J., 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine 368: 407-415. https://doi.org/10.1056/NEJMoa1205037
-
Weenen, T., 2014. On the origin and development of the medical nutrition industry. Erasmus School of Economics, Rotterdam, the Netherlands.
'On the origin and development of the medical nutrition industry', ().
-
Weenen, T.C., Jentink, A., Pronker, E.S., Commandeur, H.R. and Claassen, E., 2013. A decision framework to evaluate intellectual property strategies in the medical nutrition market. PharmaNutrition 1: 65-72. https://doi.org/10.1016/j.phanu.2013.02.002
-
World Health Organization of the United Nations (WHO), 2021. International classification of diseases, 11th revision. WHO, Geneva, Switzerland.
-
World Intellectual Property Organization (WIPO), 2021. International patent classification. Available at: https://tinyurl.com/2xzse37p.
Supplementary Materials
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 581 | 221 | 37 |
| Full Text Views | 25 | 6 | 1 |
| PDF Views & Downloads | 41 | 8 | 0 |
Innovations for microbiome targeting interventions â a patent landscape analysis indicating overall patenting activity decline and promising target disease areas
In: Beneficial MicrobesSearch for other papers by J.K. Timmis in
Current site
Google Scholar
PubMed
Search for other papers by D. Flaherty Roussilhon in
Current site
Google Scholar
PubMed
Search for other papers by L.H.M. van de Burgwal in
Current site
Google Scholar
PubMed
The human microbiota have been implicated in the aetiology and remedy of a host of disorders. However, due to the pervasive uncertainty inherent in the field of microbiota-targeting interventions and associated issues with establishing rigorous safety and efficacy profiles, regulatory oversight is suboptimal. This can dissuade innovators from further exploring novel and much needed health interventions. Modification of regulatory protocols and practices requires focussed efforts and funding to build the evidence base around future regulatory needs. Such modification can be critically informed by identification of changes and trends in technology fields to facilitate identification of regulatory gaps. To this purpose, this study rigorously collected and analysed patent data from Espacenet â covering the years 2013-2018 â and created a patent landscape analysis of microbiome targeting interventions with a focus on medicinal products. Pertinent patenting activity has declined overall. While, in absolute terms, patents most frequently claimed inventions targeting disorders of the gut and alimentary tract, relative year-on-year interest increases have been substantial for cancer, and disorders of the (neuro-)muscular and respiratory systems â driven by the private sector. Academic stakeholders showed top interest in disorders of the metabolism, anti-infectives, and skeletal and dermatological diseases. Although medicinal preparation claims dominated our dataset, a third of patents claimed food preparations, while only 1% claimed application as a diagnostic. Finally, China is, by an inordinate margin, a market of particular interest for both domestic and foreign innovators, indicating that microbiome targeting intervention innovation for EU and US markets might be frustrated. This study is the first to empirically demonstrate that live biotherapeutic product innovation is decelerating and potentially frustrated, supporting the urgent need for improved regulatory standards. Our results indicate which disease areas deserve particular attention for research funding to facilitate proper regulatory appraisal in the near- to mid-term future.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 581 | 221 | 37 |
| Full Text Views | 25 | 6 | 1 |
| PDF Views & Downloads | 41 | 8 | 0 |
